Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 and ACZ885 in Polymyalgia Rheumatica
NCT01364389Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2011
- Primary completion
- Jan 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of secukinumab and canakinumab in polymyalgia rheumatica (PMR) (3 arms), sponsored by Novartis. Primary endpoint: Polymyalgia Rheumatica Activity Score at Day 15. Started Feb 2011; status: terminated.
02
Drugs
secukinumabcanakinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT01364389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01364389.